0      0

eSymposia | Antibodies and Vaccines as Drugs for COVID-19


ek31-esym-session-Stumpp-Michael - Highly Potent Anti‑SARS‑CoV‑2 Multivalent DARP in Therapeutic Candidates


Jan 13, 2021 10:55am ‐ Jan 13, 2021 11:10am

Speaker(s):

You must be logged in and own this session in order to post comments.

Leo OzurumbaDwight
1/13/21 11:56 am

Nice study sir. Congrats on this effort by your research team. With this qualities from Anti‑SARS‑CoV‑2 Multivalent DARP molecules reported h in your published work on this candidate, which included high antiviral effect, high yield, long systemic half-life, it is an impressive work undeed. As your team stated, it could have potential for single-dose use in clinical usage. This potential will then be your focus to validate it. If it comes out fine, which we hope, then we could have another clinical tool against Covid19 in our hands. Warm regards. Leo Ozurumba-Dwight

Leo OzurumbaDwight
1/13/21 12:00 pm

Reference from your team's pre-print version: Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates Marcel Walser, Sylvia Rothenberger, Daniel L. Hurdiss, et al.. COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv. I commend this team. Warm regards. Leo Ozurumba-Dwight

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content